Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases

Monoclonal antibody (MoAb)-based therapies have opened innovative treatment avenues that have impacted on the management of patients with both neoplastic and non-neoplastic hematological diseases. The aim of our study was to evaluate in a large series of cases of acute lymphoblastic leukemia (ALL) the expression of specific antigens, CD19, CD20, CD22, and CD33, for which MoAbs are available for clinical use. For each antigen, evaluation was based on the percentage of positive leukemic cells and the degree of antigen expression by mean fluorescence intensity (MFI) and antibody binding capacity (ABC) that were correlated with age, immunophenotype, and presence/absence of particular molecular markers. We can document that some of the analyzed antigens showed a degree of expression related to the B-cell maturation profile, and that the antigen expression intensity appeared to vary according to the presence of specific genetic markers. These findings suggest that the possible clinical use of a given MoAb in patients with ALL should take into account both the maturation profile of the leukemic cells and the presence of a given molecular transcript. Only clinical studies will conclusively demonstrate whether the differences in antigenic expression truly correlate with the different therapeutic efficacies of the various clinical grade MoAbs.

[1]  L. Lanier,et al.  Eri1 regulates microRNA homeostasis and mouse lymphocyte development and antiviral function. , 2012, Blood.

[2]  H. Einsele,et al.  CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia , 2010 .

[3]  T. Lipp,et al.  Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003 , 2010 .

[4]  T. Cooper,et al.  CD20 up-Regulation In Induction Therapy for Childhood B Lymphoblastic Leukemia , 2010 .

[5]  G. Basso,et al.  Modulation of antigen expression in B‐cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug‐induced regulatory phenomenon. Results of the AIEOP‐BFM‐ALL‐FLOW‐MRD‐Study Group , 2010, Cytometry. Part B, Clinical cytometry.

[6]  C. Pui.  Toward a total cure for acute lymphoblastic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Kantarjian,et al.  Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. , 2009, Blood.

[8]  P. Chevallier,et al.  Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases , 2009, Leukemia.

[9]  P. Kufer,et al.  Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. , 2009, Leukemia research.

[10]  P. Kufer,et al.  Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study. , 2008 .

[11]  G. Basso,et al.  CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. , 2008, Blood.

[12]  Holly M Horton,et al.  Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. , 2008, Cancer research.

[13]  P. Chevallier,et al.  Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression , 2008, International journal of hematology.

[14]  M. Borowitz,et al.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Stanciu-Herrera,et al.  Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines. , 2008, Leukemia research.

[16]  H. Kantarjian,et al.  Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). , 2007 .

[17]  A. Vora,et al.  Remission induction with single agent Rituximab in a child with multiply relapsed precursor‐B ALL , 2007, British journal of haematology.

[18]  R. Foà,et al.  Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. , 2007, Haematologica.

[19]  R. Foà,et al.  The changing scene of adult acute lymphoblastic leukemia , 2006, Current opinion in oncology.

[20]  R. Wells.  Induction therapy for adults with acute lymphoblastic leukemia , 2006, Current oncology reports.

[21]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[22]  M. Andreeff,et al.  Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL). , 2005 .

[23]  M. Béné.  Immunophenotyping of acute leukaemias. , 2005, Immunology letters.

[24]  P. Kuriakose.  Targeted therapy for hematologic malignancies. , 2005, Cancer control : journal of the Moffitt Cancer Center.

[25]  R. Giavazzi,et al.  Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo , 2005, British journal of haematology.

[26]  Francisco Ortuño,et al.  Immunophenotyping of acute leukemias and myelodysplastic syndromes , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[27]  D. Hoelzer,et al.  Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects , 2004, Annals of Hematology.

[28]  J. Leonard,et al.  Epratuzumab: targeting B-cell malignancies through CD22. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  A. O'marcaigh,et al.  Successful use of gemtuzumab ozogamicin in a child with relapsed cd33‐positive acute lymphoblastic leukaemia , 2003, British journal of haematology.

[30]  D. Reinhardt,et al.  Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin , 2003, Leukemia.

[31]  R. Foà,et al.  A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. , 2003, Haematologica.

[32]  R. Foà,et al.  A multiplex reverse transcription-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes : a clinical evaluation on 170 patients with acute lymphoblastic leukemia , 2003 .

[33]  R. Foà,et al.  Towards an integrated classification of adult acute lymphoblastic leukemia. , 2002, Reviews in clinical and experimental hematology.

[34]  A. Órfão,et al.  Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression , 2001, Leukemia.

[35]  D. Hoelzer,et al.  Recent approaches in acute lymphoblastic leukemia in adults. , 2002, Critical reviews in oncology/hematology.

[36]  J V Giorgi,et al.  Quantitation of CD38 expression using QuantiBRITE beads. , 1998, Cytometry.

[37]  R. Hoffman,et al.  Determination of CD4 antigen density on cells: role of antibody valency, avidity, clones, and conjugation. , 1998, Cytometry.